Memantin Hcs

Memantine, the active ingredient in Memantin Hcs, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used in the management of moderate to severe Alzheimer’s disease in adult patients. GNH USA supplies Memantin Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Hcs is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease and related cognitive disorders. - Alzheimer’s disease (mild to moderate): helps improve cognition and daily functioning. - Alzheimer’s disease (moderate to severe): may slow the progression of memory loss and functional decline. - Alzheimer’s disease with behavioral symptoms: can reduce agitation and improve overall patient behavior.

Memantin Hcs may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness or imbalance. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Seizures: new onset or worsening of seizure activity. - Cardiac arrhythmia: irregular heart rhythm. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Suicidal thoughts: emergence of depressive or suicidal ideation.

When prescribing Memantin Hcs, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: assess blood pressure and heart rate regularly. - Concurrent NMDA antagonists: avoid co‑administration to reduce neurotoxicity risk. - Pregnancy: safety unknown; use only if potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantin Hcs can interact with other medicines, necessitating careful review of a patient’s regimen.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxic effects. - Ketamine: additive NMDA blockade can lead to excessive CNS depression. - Other NMDA antagonists: concurrent use should be avoided.

Moderate Interactions (Monitor Closely): - Antihypertensives: memantine may enhance hypotensive effects. - Anticholinergic agents: may worsen cognitive impairment when used together.